Government-Owned Inventions; Availability for Licensing, 7215-7217 [2014-02490]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 25 / Thursday, February 6, 2014 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
detecting retroviruses within a patient
blood sample and discriminating HIV–
1 samples within serum specimens.
HIV–1 can be genetically classified into
two major groups, group M (major) and
Group O (outlier) with group O
comprising all divergent viruses that do
not cluster with group M. The
identification of group O infections
raised public health concerns about the
safety of the blood supply because HIV–
1 screening by group M-based serologic
tests does not consistently detect group
O infection.
The assay is based on the selective
inhibition of Amp-RT reactivity of
Group M viruses by nevirapine, a nonnucleoside RT inhibitor. Group O
viruses can be generically identified by
the resistance of their Amp-RT activity
to nevirapine. The assay can be used to
screening of the blood supply and to
rapidly differentiate group M from
group O virus.
Potential Commercial Applications:
• Clinical monitoring of individual
patient antiretroviral therapy
• HIV/AIDS public health programs
• Surveillance of retroviral drug
resistance
• Screening of blood donations
Competitive Advantages:
• Rapid diagnostic which greatly
reduces time and labor for improved
clinical monitoring of HIV treatment
• Ready for commercialization
• Easily adapted to kit format
• Assists continued usefulness of
common antiretroviral therapeutics
• Useful for high-throughput serum
samples screening
Development Stage: In vitro data
available
Inventors: Thomas M. Folks, Walid
Heneine, William Marshall Switzer,
Shinji Yamamoto (all of CDC)
Publications:
1. Yamamoto S, et al. Highly sensitive
qualitative and quantitative detection of
reverse transcriptase activity:
Optimization, validation, and
comparative analysis with other
detection systems. J Virol Methods. 1996
Sep;61(1–2):135–43. [PMID 8882946]
2. Heneine W, et al. Detection of reverse
transcriptase by a highly sensitive assay
in sera from persons infected with
human immunodeficiency virus type 1.
J Infect Dis. 1995 May;171(5):1210–6.
[PMID 7538549]
3. Reisler RB, et al. Early detection of reverse
transcriptase activity in plasma of
neonates infected with HIV–1: A
comparative analysis with RNA-based
and DNA-based testing using polymerase
chain reaction. J Acquir Immune Defic
Syndr. 2001 Jan 1;26(1):93–102. [PMID
11176273]
Intellectual Property:
VerDate Mar<15>2010
18:18 Feb 05, 2014
Jkt 232001
HHS Reference No. E–232–1993/0 —
• PCT Application No. PCT/US1996/
001257 filed 26 Jan 1996, which
published as WO 1996/023076 on 01
Aug 1996
• Various international patents issued or
pending
HHS Reference No. E–232–1993/1—
• U.S. Patent No. 5,849,494 issued 15 Dec
1998
• U.S. Patent No. 6,136,534 issued 24 Oct
2000
Related Technologies:
HHS Reference No. E–129–2013/0—
• PCT Application No. PCT/US1999/
013957 filed 16 Jun 1999, which
published as WO 1999/66068 on 23 Dec
1999
• U.S. Patent No. 6,787,126 issued 07 Sep
2004
• Various international patents issued
HHS Reference No. E–129–2013/1—
• U.S. Patent No. 7,691,572 issued 06 Apr
2010
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov
Dated: January 31, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–02491 Filed 2–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
7215
be required to receive copies of the
patent applications.
Multivalent Immunogenic Peptides
(Vaccines) for the Treatment of Prostate
and Breast Cancer
Description of Technology: The
development of more targeted means of
treating cancer is vital. One option for
a targeted treatment is the creation of a
vaccine that induces an immune
response only against cancer cells. In
this sense, vaccination involves the
introduction of a peptide into a patient
that causes the formation of antibodies
or T cells that recognize the peptide. If
the peptide is from a protein found
selectively on/in cancer cells, those
antibodies or T cells can trigger the
death of those cancer cells without
harming non-cancer cells. This can
result in fewer side effects for the
patient.
TARP (T cell receptor gamma
alternate reading frame protein) is a
protein that is selectively expressed on
the cells of about 95% of prostate
cancers and about 50% of breast
cancers. This invention concerns the
identification of a combination of
immunogenic peptides within TARP
and their use to create an anti-cancer
immune response in patients. By
introducing these seven peptides into a
patient, an immune response against
these cancer cells can be initiated by the
peptides, resulting in treatment of the
cancer.
Potential Commercial Applications:
• Peptides can be used as vaccines to
induce an immune response against
cancer
• Treatment of any cancer associated
with increased or preferential
expression of TARP
• Specific diseases include breast
cancer and prostate cancer
Competitive Advantages:
• Targeted therapy decreases nonspecific killing of healthy, essential
cells, resulting in fewer non-specific
side-effects and healthier patients
• Use of multiple peptides permits
production of a more thorough
complement of T cells against the
antigen
Development Stage:
• In vitro data available
• In vivo data available (animal)
• In vivo data available (human)
Inventors: Jay A. Berzofsky, et al.
(NCI)
Publications:
1. Epel M, et al. Targeting TARP, a novel
breast and prostate tumor-associated
antigen, with T cell receptor-like human
recombinant antibodies. Eur J Immunol.
2008 Jun;38(6):1706–20. [PMID
E:\FR\FM\06FEN1.SGM
06FEN1
7216
Federal Register / Vol. 79, No. 25 / Thursday, February 6, 2014 / Notices
18446790]
2. Oh S, et al. Human CTLs to wild-type and
enhanced epitopes of a novel prostate
and breast tumor-associated protein,
TARP, lyse human breast cancer cells.
Cancer Res. 2004 Apr 1;64(7):2610–8.
[PMID 15059918]
Intellectual Property: HHS Reference
No. E–047–2014/0—US Provisional
Patent Application No. 61/915,948 filed
13 Dec 2013
Related Technologies: HHS Reference
No. E–116–2003/0—
• U.S. Patent No. 8,043,623 issued 02
Jun 2009
• U.S. Patent No. 7,541,035 issued 25
Oct 2011
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov
Collaborative Research Opportunity:
The Vaccine Branch, CCR, NCI, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
cancer vaccines to induce T cell
immunity against TARP to treat prostate
and/or breast cancer. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at hewesj@mail.nih.gov.
mstockstill on DSK4VPTVN1PROD with NOTICES
Novel Immunocytokine for the
Treatment of Cancer
Description of Technology:
Mesothelin is a protein that is aberrantly
expressed by several cancers, most
notably malignant mesothelioma.
Immunoconjugates that target
mesothelin are currently being
evaluated in clinical trials.
Unfortunately, these immunoconjugates
often use bacterial toxins as the payload,
leading to the formation of neutralizing
antibodies by patients and resulting in
a reduction in therapeutic effectiveness
over multiple administrations.
Interleukin-12 (IL12) is a protein that
has potent anti-tumor, anti-angiogenic,
and anti-metastatic properties. Although
initially considered an attractive
candidate as a cancer therapeutic,
systemic administration of IL12 is toxic.
Inventors at the NIH have created an
immunoconjugate using an antimesothelin antibody (SS1) as the
targeting moiety and IL12 as the payload
molecule. This allows the localized
concentration of IL12 at cancer cells,
reducing the toxic effects seen with
systemic IL12 administration.
Furthermore, using IL12 instead of a
bacterial toxin helps to reduce the
formation of neutralizing antibodies.
The IL12–SS1 immunoconjugate is able
to inhibit the growth human malignant
mesothelioma in mouse xenograft
models, suggesting it has significant
potential as a cancer therapeutic.
VerDate Mar<15>2010
18:18 Feb 05, 2014
Jkt 232001
Potential Commercial Applications:
• Selective killing of cells that express
mesothelin, such as those seen with
particular cancers.
• Specific cancers include malignant
mesothelioma, pancreatic cancer and
ovarian cancer.
Competitive Advantages:
• Targeted therapy decreases nonspecific killing of healthy, essential
cells, resulting in fewer non-specific
side-effects and healthier patients.
• Use of human IL12 as the payload
may reduce formation of neutralizing
antibodies against the molecule,
increasing therapeutic effectiveness.
Development Stage:
• In vitro data available
• In vivo data available (animal)
Inventors: Mitchell Ho, et al. (NCI)
Publication:
Kim H, et al. Novel immunocytokine IL12–
SS1(Fv) inhibits mesothelioma tumor
growth in nude mice. PLoS One. 2013
Nov 15;8(11):e81919. [PMID 24260587]
Intellectual Property: HHS Reference
No. E–118–2013/0—US Provisional
Patent Application 61/820,523 filed 07
May 2013
Related Technology: HHS Reference
No. E–139–1999/0—U.S. Patent
7,081,518 issued 25 July 2006
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov
Collaborative Research Opportunity:
The NCI Laboratory of Molecular
Biology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize the immunocytokinebased therapy targeting mesothelinexpressing tumors. For collaboration
opportunities, please contact John
Hewes, Ph.D. at hewesj@mail.nih.gov.
Improved Personalized Cancer
Immunotherapy: Rapid Selection of
Tumor Reactive T Cells Based on
Expression of Specific Cell Surface
Markers From Peripheral Blood
Description of Technology: Scientists
at NIH have identified a process to
select highly tumor-reactive T cells from
a patient’s peripheral blood sample
based on the expression of two specific
T cell surface markers: programmed cell
death protein 1 (PD–1; CD279) and/or T
cell Ig- and mucin-domain-containing
molecule-3 (TIM–3). After this enriched
population of tumor-reactive T cells is
selected and expanded to large
quantities, it gets re-infused into the
patient via an adoptive cell transfer
(ACT) regimen. The key finding for this
process is that the most tumor-reactive
T cells found in a bulk population of
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
cells obtained from a patient’s
peripheral blood sample reliably exhibit
high expression of at least one of these
markers. The enrichment of tumorreactive cells from a patient’s peripheral
blood based on these markers provides
and simple alternative to the current
strategies based on isolation tumorreactive cells from the tumor, as it
reduces the cost and complications of
tumor resection, as well as provides a T
cell product for patients without
resectable lesions.
This new method for selecting tumorreactive T cells from peripheral blood
samples should help ACT
immunotherapy become more GMP
compliant and allow greater
standardized of the production process
to enable more widespread utilization of
this personalized cancer treatment
approach outside of NIH.
Potential Commercial Applications:
• Personalized ACT immunotherapy to
treat cancers using T cells obtained
from a peripheral blood.
• Possible integration into a standard
procedure for obtaining tumorreactive T cells from a peripheral
blood as part of a GMP-compliant
manufacturing process that gains
regulatory approval as a personalized
cancer treatment option.
• The immunotherapy component of a
combination cancer therapy regimen
targeting specific tumor antigens in
individual patients.
• More rapid tumor-reactive T cell
culturing process for laboratory
testing.
Competitive Advantages:
• Simpler: Tumor-reactive T cells can
be selected for ACT from a bulk
population derived from peripheral
blood sample using common
laboratory techniques.
• More rapid: Selection of T cells based
on expression of specific cell surface
markers will reduce the culture time
for these T cells before reinfusion into
the patient to fight the tumor.
• Less screening: This selection method
eliminates the need to screen T cells
for autologous tumor recognition
before re-infusion into the patient.
Development Stage:
• Early-stage
• In vitro data available
Inventors: Alena Gros and Steven A.
Rosenberg (NCI)
Intellectual Property: HHS Reference
No. E–085–2013/0—
• U.S. Provisional Application No. 61/
771,251 filed 01 March 2013
• PCT Application No. PCT/US2013/
38813 filed 30 April 2013
Related Technologies: HHS Reference
No. E–059–2013—
E:\FR\FM\06FEN1.SGM
06FEN1
Federal Register / Vol. 79, No. 25 / Thursday, February 6, 2014 / Notices
• US Provisional Application No. 61/
771,247 filed 01 March 2013
• PCT Application No. PCT/US2013/
038799 filed 30 April 2013
Licensing Contact: Whitney A.
Hastings; 301–451–7337; hastingw@
mail.nih.gov
Dated: January 31, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
Branch, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, 6001 Executive Blvd., Room 4226,
MSC 9550, Bethesda, MD 20892–9550, 301–
435–1432, liangm@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS).
Dated: January 30, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–02460 Filed 2–5–14; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK4VPTVN1PROD with NOTICES
[FR Doc. 2014–02490 Filed 2–5–14; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; R13
Conference Grant Review (PA12–212).
Date: March 4, 2014.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Virtual
Meeting).
Contact Person: Minna Liang, Ph.D.,
Scientific Review Officer, Grants Review
Branch, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, 6001 Executive Blvd., Room 4226,
MSC 9550, Bethesda, MD 20892–9550, 301–
435–1432, liangm@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
I/START Small Grant Review.
Date: March 6, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Virtual
Meeting).
Contact Person: Minna Liang, Ph.D.,
Scientific Review Officer, Grants Review
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NonClinical ADME Studies (8916).
Date: March 11, 2014.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 435–1439, lf33c.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Data,
Statistics, and Clinical Trial Support (2237).
Date: March 13, 2014.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
VerDate Mar<15>2010
18:18 Feb 05, 2014
Jkt 232001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
7217
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 435–1439, lf33c.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
NIDAMED: Outreach and Education to
Health Care Providers on Substance Use
(1152).
Date: March 20, 2014.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 435–1439, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS).
Dated: January 30, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–02461 Filed 2–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging And Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; P41 BTRC Review.
Date: March 6–7, 2014.
Time: 3:00 p.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: TownePlace Suites Marriott, Albany
Downtown/Medical Center, 22 Holland
Avenue, Albany, NY.
E:\FR\FM\06FEN1.SGM
06FEN1
]]>Agencies
[Federal Register Volume 79, Number 25 (Thursday, February 6, 2014)]
[Notices]
[Pages 7215-7217]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-02490]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Multivalent Immunogenic Peptides (Vaccines) for the Treatment of
Prostate and Breast Cancer
Description of Technology: The development of more targeted means
of treating cancer is vital. One option for a targeted treatment is the
creation of a vaccine that induces an immune response only against
cancer cells. In this sense, vaccination involves the introduction of a
peptide into a patient that causes the formation of antibodies or T
cells that recognize the peptide. If the peptide is from a protein
found selectively on/in cancer cells, those antibodies or T cells can
trigger the death of those cancer cells without harming non-cancer
cells. This can result in fewer side effects for the patient.
TARP (T cell receptor gamma alternate reading frame protein) is a
protein that is selectively expressed on the cells of about 95% of
prostate cancers and about 50% of breast cancers. This invention
concerns the identification of a combination of immunogenic peptides
within TARP and their use to create an anti-cancer immune response in
patients. By introducing these seven peptides into a patient, an immune
response against these cancer cells can be initiated by the peptides,
resulting in treatment of the cancer.
Potential Commercial Applications:
Peptides can be used as vaccines to induce an immune response
against cancer
Treatment of any cancer associated with increased or
preferential expression of TARP
Specific diseases include breast cancer and prostate cancer
Competitive Advantages:
Targeted therapy decreases non-specific killing of healthy,
essential cells, resulting in fewer non-specific side-effects and
healthier patients
Use of multiple peptides permits production of a more thorough
complement of T cells against the antigen
Development Stage:
In vitro data available
In vivo data available (animal)
In vivo data available (human)
Inventors: Jay A. Berzofsky, et al. (NCI)
Publications:
1. Epel M, et al. Targeting TARP, a novel breast and prostate tumor-
associated antigen, with T cell receptor-like human recombinant
antibodies. Eur J Immunol. 2008 Jun;38(6):1706-20. [PMID
[[Page 7216]]
18446790]
2. Oh S, et al. Human CTLs to wild-type and enhanced epitopes of a
novel prostate and breast tumor-associated protein, TARP, lyse human
breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2610-8. [PMID
15059918]
Intellectual Property: HHS Reference No. E-047-2014/0--US
Provisional Patent Application No. 61/915,948 filed 13 Dec 2013
Related Technologies: HHS Reference No. E-116-2003/0--
U.S. Patent No. 8,043,623 issued 02 Jun 2009
U.S. Patent No. 7,541,035 issued 25 Oct 2011
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov
Collaborative Research Opportunity: The Vaccine Branch, CCR, NCI,
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
cancer vaccines to induce T cell immunity against TARP to treat
prostate and/or breast cancer. For collaboration opportunities, please
contact John D. Hewes, Ph.D. at hewesj@mail.nih.gov.
Novel Immunocytokine for the Treatment of Cancer
Description of Technology: Mesothelin is a protein that is
aberrantly expressed by several cancers, most notably malignant
mesothelioma. Immunoconjugates that target mesothelin are currently
being evaluated in clinical trials. Unfortunately, these
immunoconjugates often use bacterial toxins as the payload, leading to
the formation of neutralizing antibodies by patients and resulting in a
reduction in therapeutic effectiveness over multiple administrations.
Interleukin-12 (IL12) is a protein that has potent anti-tumor,
anti-angiogenic, and anti-metastatic properties. Although initially
considered an attractive candidate as a cancer therapeutic, systemic
administration of IL12 is toxic.
Inventors at the NIH have created an immunoconjugate using an anti-
mesothelin antibody (SS1) as the targeting moiety and IL12 as the
payload molecule. This allows the localized concentration of IL12 at
cancer cells, reducing the toxic effects seen with systemic IL12
administration. Furthermore, using IL12 instead of a bacterial toxin
helps to reduce the formation of neutralizing antibodies. The IL12-SS1
immunoconjugate is able to inhibit the growth human malignant
mesothelioma in mouse xenograft models, suggesting it has significant
potential as a cancer therapeutic.
Potential Commercial Applications:
Selective killing of cells that express mesothelin, such as
those seen with particular cancers.
Specific cancers include malignant mesothelioma, pancreatic
cancer and ovarian cancer.
Competitive Advantages:
Targeted therapy decreases non-specific killing of healthy,
essential cells, resulting in fewer non-specific side-effects and
healthier patients.
Use of human IL12 as the payload may reduce formation of
neutralizing antibodies against the molecule, increasing therapeutic
effectiveness.
Development Stage:
In vitro data available
In vivo data available (animal)
Inventors: Mitchell Ho, et al. (NCI)
Publication:
Kim H, et al. Novel immunocytokine IL12-SS1(Fv) inhibits
mesothelioma tumor growth in nude mice. PLoS One. 2013 Nov
15;8(11):e81919. [PMID 24260587]
Intellectual Property: HHS Reference No. E-118-2013/0--US
Provisional Patent Application 61/820,523 filed 07 May 2013
Related Technology: HHS Reference No. E-139-1999/0--U.S. Patent
7,081,518 issued 25 July 2006
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov
Collaborative Research Opportunity: The NCI Laboratory of Molecular
Biology is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate or
commercialize the immunocytokine-based therapy targeting mesothelin-
expressing tumors. For collaboration opportunities, please contact John
Hewes, Ph.D. at hewesj@mail.nih.gov.
Improved Personalized Cancer Immunotherapy: Rapid Selection of Tumor
Reactive T Cells Based on Expression of Specific Cell Surface Markers
From Peripheral Blood
Description of Technology: Scientists at NIH have identified a
process to select highly tumor-reactive T cells from a patient's
peripheral blood sample based on the expression of two specific T cell
surface markers: programmed cell death protein 1 (PD-1; CD279) and/or T
cell Ig- and mucin-domain-containing molecule-3 (TIM-3). After this
enriched population of tumor-reactive T cells is selected and expanded
to large quantities, it gets re-infused into the patient via an
adoptive cell transfer (ACT) regimen. The key finding for this process
is that the most tumor-reactive T cells found in a bulk population of
cells obtained from a patient's peripheral blood sample reliably
exhibit high expression of at least one of these markers. The
enrichment of tumor-reactive cells from a patient's peripheral blood
based on these markers provides and simple alternative to the current
strategies based on isolation tumor-reactive cells from the tumor, as
it reduces the cost and complications of tumor resection, as well as
provides a T cell product for patients without resectable lesions.
This new method for selecting tumor-reactive T cells from
peripheral blood samples should help ACT immunotherapy become more GMP
compliant and allow greater standardized of the production process to
enable more widespread utilization of this personalized cancer
treatment approach outside of NIH.
Potential Commercial Applications:
Personalized ACT immunotherapy to treat cancers using T cells
obtained from a peripheral blood.
Possible integration into a standard procedure for obtaining
tumor-reactive T cells from a peripheral blood as part of a GMP-
compliant manufacturing process that gains regulatory approval as a
personalized cancer treatment option.
The immunotherapy component of a combination cancer therapy
regimen targeting specific tumor antigens in individual patients.
More rapid tumor-reactive T cell culturing process for
laboratory testing.
Competitive Advantages:
Simpler: Tumor-reactive T cells can be selected for ACT from a
bulk population derived from peripheral blood sample using common
laboratory techniques.
More rapid: Selection of T cells based on expression of
specific cell surface markers will reduce the culture time for these T
cells before reinfusion into the patient to fight the tumor.
Less screening: This selection method eliminates the need to
screen T cells for autologous tumor recognition before re-infusion into
the patient.
Development Stage:
Early-stage
In vitro data available
Inventors: Alena Gros and Steven A. Rosenberg (NCI)
Intellectual Property: HHS Reference No. E-085-2013/0--
U.S. Provisional Application No. 61/771,251 filed 01 March
2013
PCT Application No. PCT/US2013/38813 filed 30 April 2013
Related Technologies: HHS Reference No. E-059-2013--
[[Page 7217]]
US Provisional Application No. 61/771,247 filed 01 March 2013
PCT Application No. PCT/US2013/038799 filed 30 April 2013
Licensing Contact: Whitney A. Hastings; 301-451-7337;
hastingw@mail.nih.gov
Dated: January 31, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-02490 Filed 2-5-14; 8:45 am]
BILLING CODE 4140-01-P
